Welcome and introduction to IMI

Andrzej Jan Rys
Directorate-General for Health and Consumers,
European Commission,
IMI Governing Board
Why IMI?

- Decline in R&D industrial productivity despite steadily increasing R&D expenditures
  => research bottlenecks in the drug development process
- Loss of European competitiveness in the sector
- Europe is good at putting stakeholders together, based on the EU experience from the Framework Programmes
- Europe has the potential and capacity of innovation, based on a tissue of entrepreneurial universities and SMEs
- Common initiative EC – Pharma industry
- Faster and better drugs for the patient
IMI Objectives

Better and faster medicines for patients

New pre-competitive research tools

The IMI JU is a Public-Private Partnership

New approach to support research in FP7 Health Theme

Re-invigorate the drug development process

Increase competitiveness EU pharma sector

Better and faster medicines for patients
**IMI particular features**

- Problem-solving approach and precompetitive research
- Potential to address unmet medical needs ("unlock" a specific area)
- Dialogue with the regulatory authorities
- Work beyond usual habits
  - Participation to large and new types of partnerships.
  - Data and knowledge sharing at larger scale.
- New research tools to be rapidly and broadly spread and taken up within the scientific and industrial community
  - A tailor-made IMI intellectual property policy provides the adequate provisions to support this challenge
What do we expect for IMI

• Address open innovation
• Address unmet Medical needs
• Guarantee uptake of new scientific and industrial precompetitive research tools
• Tool to reinvigorate drug development for the benefit of patients
• Consolidate research networks and PP collaboration
What is achieved

• 2 calls implemented:
  – 23 projects running in 2011 with ~190M€ from IMI JU and ~200 M€ from EFPIA companies

• 3rd call projects under negotiation
• 4th Call launched in July 2011

• Update of scientific research agenda summer 2011
• Solid reflection on remaining Calls engaged
• Interim evaluation of IMI JU finalised
### SME involvement in IMI projects

<table>
<thead>
<tr>
<th>Call</th>
<th>Number of SME</th>
<th>SME funding</th>
<th>Total Funding</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Call 1</td>
<td>25</td>
<td>14.602.472</td>
<td>109.593.433</td>
<td>13.32%</td>
</tr>
<tr>
<td>Call 2</td>
<td>22</td>
<td>15.455.411</td>
<td>80.740.072</td>
<td>19.14%</td>
</tr>
<tr>
<td>Call 1 and 2</td>
<td>47</td>
<td>30.057.883</td>
<td>190.333.505</td>
<td>15.79%</td>
</tr>
</tbody>
</table>

SMEs involved in all projects except the education and training projects from the first call
What next?

IMI 4th Call (2011) closing date 18 October 2011, particular effort on Knowledge Management

The remaining calls will bring:

- Larger projects for some topics
- Special focus on knowledge management to harness the wealth of data generated by IMI projects
Outlook

• **Innovation at the heart of the Europe 2020 strategy for growth and jobs: Innovation Union**

• **Commission green paper on a Common Strategic Framework for European research:**
  – Focus on world-beating science base, boosting competitiveness, tackling grand challenges such as health and ageing population
  – Making EU funding more attractive and easier to access; funding instruments covering the full innovation chain, including basic research, applied research, collaboration between academia and industry and firm-level innovation
  – Simpler and more consistent accounting procedures for use of funds

• Commission will make legislative proposal before end of 2011

• Part of the 2014-2020 multiannual financial framework
What about the future?

• Harvesting on the results from ongoing projects
• Define performance indicators and assess impact of IMI.
• Define « IdealHouse » for PPP. How does/will IMI fit in this?
• What about IMI.2? If any, what would it look like?
More about IMI: www.imi.europa.eu